An Investigational New Drug for the Treatment of Alzheimer’s Disease
Official Title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Escalating Doses of LH-001 in Healthy Subjects
Purpose
The purpose of this study is to evaluate the safety and tolerability of an investigational new drug in healthy participants aged 18-60 years.
Could this study be right for you?
- In good health and BMI (ratio of body weight to height) between 18-26 kg/m2
- Willing to participate in various research assessments including blood collection, urine collection, electrocardiogram, and vital signs
- Willing to stay overnight (~30 hours) in the OSU Hospital Clinical Research Center
- If sexually active, willing to utilize highly effective birth control during the study period
- Not currently pregnant or breast-feeding
- No significant medical condition involving any major organs (heart, lung, liver, brain, or endocrine)
- No any of the following: cancer, alcohol or substance abuse, spleen problems, or drug hypersensitivity
- No history of or undergoing treatment for: major psychiatric illness, seizures, or autoimmune disease
- Not currently taking immunosuppressive drugs
- No active Hepatitis B, Hepatitis C, or HIV